Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3

Conditions

Colorectal Neoplasms 260Carcinoma, Non-Small-Cell Lung 125Glioblastoma 105Breast Neoplasms 104Ovarian Neoplasms 96Carcinoma, Hepatocellular 88Brain Neoplasms 71Rectal Neoplasms 69Neoplasm Metastasis 69Lung Neoplasms 65Colonic Neoplasms 58Neoplasms 57Glioma 52Fallopian Tube Neoplasms 44Carcinoma, Renal Cell 36Gliosarcoma 31Pancreatic Neoplasms 30Melanoma 27Liver Neoplasms 26Stomach Neoplasms 21Astrocytoma 21Adenocarcinoma of Lung 21Recurrence 20Kidney Neoplasms 19Colorectal Cancer Metastatic 17Triple Negative Breast Neoplasms 16Uterine Cervical Neoplasms 15Esophageal Neoplasms 15Sarcoma 13Prostatic Neoplasms 13

Interventions

Gemcitabine 9Carboplatin 8Paclitaxel 7Capecitabine 7Irinotecan 6pembrolizumab 3Radiotherapy 3Oxaliplatin 3Fluorouracil 3Filgrastim 3Cisplatin 3Bevacizumab 3etoposide phosphate 2Surveys and Questionnaires 2Peripheral Blood Stem Cell Transplantation 2Magnetic Resonance Spectroscopy 2Leucovorin 2Genetic Testing 2FAPI-46 2Etoposide 2Erlotinib Hydrochloride 2Docetaxel 2Cyclophosphamide 2Amifostine 2Albumin-Bound Paclitaxel 2tislelizumab 1tegafur-gimeracil-oteracil 1spartalizumab 1sintilimab 1erythromycin propionate-N-acetylcysteinate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Neoplasms, Unknown Primary × Bevacizumab × Clear all
NCT00458315 2015-05-08

Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor

Rigshospitalet, Denmark

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00360360 2013-12-04

Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC

Phase 2 Completed
60 enrolled 6 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00193622 2010-09-17

Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC

Phase 2 Completed
50 enrolled
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡